Swedish Orphan Biovitrum AB (publ) : Resolutions from Sobi's Annual General
The Swedish Orphan Biovitrum AB's (publ) (Sobi) AGM convened earlier today in
Stockholm and voted in favour of the resolutions proposed at the meeting,
Adoption of the profit and loss statements and balance sheet and discharge of
The AGM adopted the income statements and the balance sheets and approved the
proposal to carry forward the retained profits of SEK 4,659,221,805.
The board members and the chief executive officer were discharged from
liability for the financial year 2012.
Election of Board of Directors, remuneration to the Directors and election of
The ordinary board members Adine Grate Axén, Matthew Gantz, Bo Jesper Hansen,
Lennart Johansson, Helena Saxon, Hans GCP Shikan and Hans Wigzell were
re-elected and Bo Jesper Hansen was re-elected chairman of the Board.
The AGM approved the compensation to the Board in accordance with the
nomination committee's proposal.
PricewaterhouseCoopers AB was re-elected auditor of Sobi until the end of the
annual general meeting 2014.
The AGM approved the proposed instructions and charter for the nomination
Principles for remuneration for the management, long-term incentive program
and transfer of own shares
The AGM approved the proposed guidelines for remuneration for the management.
The AGM also approved the Board's proposal regarding the implementation of a
long-term incentive program, and hedging arrangements in respect of the
program including a directed issue of no more than 754,912 series C shares,
authorisation for the Board to decide on a repurchase of all issued series C
shares and transfers of no more than 1,719,238 own common shares to program
The Board's proposal regarding transfer of no more than 135,082 own common
shares on the stock exchange for the purpose of covering certain payments,
mainly social security contributions, that may occur in relation to the Share
Program 2010, was also approved by the AGM.
For full details on each proposal adopted by the AGM please refer to
Sobi is an international specialty healthcare company dedicated to rare
diseases. Our mission is to develop and deliver innovative therapies and
services to improve the lives of patients. The product portfolio is primarily
focused on Inflammation and Genetic diseases, with three late-stage biological
development projects within Haemophilia and Neonatology. We also market a
portfolio of specialty and rare disease products for partner companies. Sobi
is a pioneer in biotechnology with world-class capabilities in protein
biochemistry and biologics manufacturing. In 2012, Sobi had total revenues of
SEK 1.9 billion (€ 215 M) and about 500 employees. The share (STO: SOBI) is
listed on NASDAQ OMX Stockholm. More information is available at www.sobi.com
For more information please contact
Media relations Investor relations
Oskar Bosson, Head of Jörgen Winroth, Vice President, Head of Investor
T: +46 70410 71 80 T: +46 8 697 20 00
The information was released for public distribution on April 26, 2013 at
20130426_Sobi AGM resolutions 2013
This announcement is distributed by Thomson Reuters on behalf of Thomson
The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other
applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of
information contained therein.
Source: Swedish Orphan Biovitrum AB (publ) via Thomson Reuters ONE
Press spacebar to pause and continue. Press esc to stop.